PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y.o. with proven efficacy and safety. PER is registered and may also be used successfully as adjunctive treatment in therapy of primary generalized tonic-clonic seizures (PGTCS).Objective. To determine the e...

Full description

Saved in:
Bibliographic Details
Main Authors: N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
Format: Article
Language:Russian
Published: IRBIS LLC 2017-05-01
Series:Фармакоэкономика
Subjects:
refractory partial onset epilepsy
tonic-clonic seizures
perampanel
adjuvant therapy
adverse event
direct costs
pharmacoeconomics
pharmacoeconomic modeling
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/180
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items